Treating acute rejection after a kidney or kidney-pancreas transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study compares two ways of treating acute rejection (when the immune system attacks the new organ) in people who have had a kidney or combined kidney-pancreas transplant. It looks at whether adding a different approach helps protect the transplant long-term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a kidney or kidney and pancreas transplant.
- A biopsy showed acute rejection (at least borderline) that is T-cell mediated – a common type of rejection.
- You may also have some inflammation in the small blood vessels, or chronic active T-cell mediated rejection – but not antibody-mediated rejection.
- You cannot be taking certain other immune-suppressing drugs, like Rituximab, Belatacept, or JAK inhibitors.
- You are not in another investigational drug trial.
- You are able to attend study visits and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
This study looks at different treatments for a type of kidney transplant rejection called antibody-mediated rejection, where the body's immune system attacks the new kidney. It aims to understand how these treatments work and how they might help people keep their transplanted kidney healthy.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This study looks at how the immune system reacts in kidney transplant patients who may be experiencing rejection. It aims to better understand and improve treatment for transplant rejection.
Hear when a new Rejection; Transplant, Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.